irampanel and Disease-Models--Animal

irampanel has been researched along with Disease-Models--Animal* in 2 studies

Reviews

1 review(s) available for irampanel and Disease-Models--Animal

Article	Year
Irampanel Boehringer Ingelheim. Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:6 The oxazole derivative, irampanel, a non-competitive AMPA receptor antagonist, is under development by Boehringer Ingelheim for the potential treatment of stroke [329079]. Phase I/IIa trials for stroke had been initiated by July 2000 [374144]. Phase II trials were ongoing in April 2001 [407163]; in April 2002, however, the drug did not appear on the company's research and development pipeline [446554], and a company spokesperson declined to confirm its current status [450591]. The compound was also originally under investigation for other neurological disorders, including epilepsy and pain [329079], although by October 1999, development was only ongoing for stroke [346080]. Topics: Animals; Clinical Trials, Phase I as Topic; Disease Models, Animal; Humans; Oxadiazoles; Receptors, AMPA; Stroke	2002

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:6

The oxazole derivative, irampanel, a non-competitive AMPA receptor antagonist, is under development by Boehringer Ingelheim for the potential treatment of stroke [329079]. Phase I/IIa trials for stroke had been initiated by July 2000 [374144]. Phase II trials were ongoing in April 2001 [407163]; in April 2002, however, the drug did not appear on the company's research and development pipeline [446554], and a company spokesperson declined to confirm its current status [450591]. The compound was also originally under investigation for other neurological disorders, including epilepsy and pain [329079], although by October 1999, development was only ongoing for stroke [346080].

Topics: Animals; Clinical Trials, Phase I as Topic; Disease Models, Animal; Humans; Oxadiazoles; Receptors, AMPA; Stroke

2002

Other Studies

1 other study(ies) available for irampanel and Disease-Models--Animal

Article	Year
The AMPA receptor/Na(+) channel blocker BIIR 561 CL is protective in a model of global cerebral ischaemia. European journal of pharmacology, 2001, Jun-15, Volume: 421, Issue:3 In this study, we investigated whether the novel neuroprotective compound dimethyl-[2-[2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-phenoxy]-ethyl]-amine hydrochloride, BIIR 561 CL, a combined non-competitive antagonist of AMPA receptors and blocker of voltage-gated Na+ channels, is protective in a rat model of severe global ischaemia. BIIR 561 CL administered immediately after 10 min of ischaemia (occlusion of both carotid arteries plus reduction of arterial blood pressure to 38-40 mm Hg) significantly reduced hippocampal damage at 4 x 26.8 mg/kg (subcutaneous injections). The competitive AMPA receptor antagonist 2,3-dihydro-6-nitro-7-sulfamoyl-benz(F)quinoxaline, NBQX, was used as a reference compound and was protective at 3x30 mg/kg (intraperitoneal and/or subcutaneous administration). BIIR 561 CL significantly reduced the ischaemia-induced premature mortality from 33.6% in the controls to 14.3%, whereas NBQX treatment had no statistically significant effect.Thus, BIIR 561 CL could be shown to reduce hippocampal damage and premature mortality in a model of severe global ischaemia. A compound with these properties might be an interesting candidate for the treatment of disorders related to global cerebral ischaemia in man. Topics: Animals; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Hippocampus; Male; Neuroprotective Agents; Oxadiazoles; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Sodium Channel Blockers; Survival Rate	2001

Article

Year

The AMPA receptor/Na(+) channel blocker BIIR 561 CL is protective in a model of global cerebral ischaemia.

European journal of pharmacology, 2001, Jun-15, Volume: 421, Issue:3

In this study, we investigated whether the novel neuroprotective compound dimethyl-[2-[2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-phenoxy]-ethyl]-amine hydrochloride, BIIR 561 CL, a combined non-competitive antagonist of AMPA receptors and blocker of voltage-gated Na+ channels, is protective in a rat model of severe global ischaemia. BIIR 561 CL administered immediately after 10 min of ischaemia (occlusion of both carotid arteries plus reduction of arterial blood pressure to 38-40 mm Hg) significantly reduced hippocampal damage at 4 x 26.8 mg/kg (subcutaneous injections). The competitive AMPA receptor antagonist 2,3-dihydro-6-nitro-7-sulfamoyl-benz(F)quinoxaline, NBQX, was used as a reference compound and was protective at 3x30 mg/kg (intraperitoneal and/or subcutaneous administration). BIIR 561 CL significantly reduced the ischaemia-induced premature mortality from 33.6% in the controls to 14.3%, whereas NBQX treatment had no statistically significant effect.Thus, BIIR 561 CL could be shown to reduce hippocampal damage and premature mortality in a model of severe global ischaemia. A compound with these properties might be an interesting candidate for the treatment of disorders related to global cerebral ischaemia in man.

Topics: Animals; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Hippocampus; Male; Neuroprotective Agents; Oxadiazoles; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Sodium Channel Blockers; Survival Rate

2001